NIAID Virology Quality Assurance
ID: 75N93024R00030Type: Solicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH NIAIDBETHESDA, MD, 20892, USA

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)

PSC

HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH (AN12)

Original Source

https://sam.gov/opp/e64368dd735844289cff403cbf42eb49/view
Timeline
    Description

    The National Institute of Allergy and Infectious Diseases (NIAID) is soliciting proposals for the Virology Quality Assurance (VQA) program under RFP number 75N93024R00030, aimed at providing comprehensive quality assessment for virologic testing related to HIV and other viral pathogens in clinical trials. The program's objectives include ensuring the validity of laboratory data through proficiency testing, real-time assay validation, and the development of performance standards, while also addressing public health emergencies and increasing laboratory demands. This initiative is crucial for maintaining high-quality laboratory practices and supporting ongoing research in virology. Proposals are due by April 8, 2025, and interested parties should direct inquiries to the primary contact, Shawnice Williams, at shawnice.williams@nih.gov or 301-761-5431.

    Point(s) of Contact
    Shawnice Williams
    (301) 761-5431
    shawnice.williams@nih.gov
    Ashley Kinderdine
    (240) 669-5154
    ashley.kinderdine@nih.gov
    Files
    Title
    Posted
    Amendment 1 RFP 75N93024R00030.pdf
    The document is an amendment to RFP No. 75N93024R00030 for the "NIAID Virology Quality Assurance," issued by NIAID under the NIH. The amendment, dated January 13, 2025, does not alter the proposal due date of April 8, 2025, and adds seven attachments, detailing the requirements for submitting proposals electronically. The main focus of the RFP is to solicit proposals for laboratory quality assurance programs for virologic assays related to HIV and other viral pathogens, ensuring accurate lab performance through proficiency testing and real-time validation controls. The Statement of Work (SOW) delineates responsibilities for conducting rigorous quality assessments, including the implementation of performance standards, statistical evaluations, and the maintenance of quality control materials. The contractor must navigate regulatory responsibilities, manage donor programs, and maintain a donor pool for acquiring necessary biological samples while ensuring compliance with ethical standards. Furthermore, provisions are made for potential contract extensions and increases in scope to cater to emerging healthcare challenges. This solicitation underscores NIAID's commitment to enhancing lab capabilities in virology for clinical applications while supporting ongoing research and public health responses.
    Sol_75N93024R00030.pdf
    The National Institute of Allergy and Infectious Diseases (NIAID) is soliciting proposals for the Virology Quality Assurance (VQA) program under RFP number 75N93024R00030, issued on January 8, 2025, with a proposal deadline set for April 8, 2025. The program aims to provide comprehensive quality assessment for virologic testing in clinical trials related to HIV and other viral pathogens. Proposals must adhere to strict submission guidelines and address various deliverables, including performance validation reports and progress updates throughout the contract period. The contract includes options for increased support in response to public health emergencies and additional laboratory demands. Key requirements also emphasize confidentiality, adherence to federal regulations, and compliance with the protection of human subjects in research. The contractor must ensure proper reporting and invoicing practices within the prescribed frameworks outlined in the solicitation. This initiative highlights the government's commitment to establishing robust quality controls in virology testing while facilitating collaborations across health agencies. Stakeholders are encouraged to direct questions to the contract specialist prior to the deadline.
    Lifecycle
    Title
    Type
    NIAID Virology Quality Assurance
    Currently viewing
    Solicitation
    NIAID Virology Quality Assurance
    Presolicitation
    NIAID Virology Quality Assurance
    Sources Sought
    Similar Opportunities
    In Vitro Assessments of Antimicrobial Activity
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking proposals for the In Vitro Assessments of Antimicrobial Activity (IVAAA) program through solicitation RFP 75N93024R00024. This initiative aims to support in vitro testing to evaluate the therapeutic potential of compounds against over 270 infectious agents, facilitating the development of vaccines, therapeutics, and diagnostics for infectious diseases. The program is critical for enhancing public health preparedness and response capabilities, particularly in addressing emerging health threats such as bioterrorism and infectious diseases. Proposals are due by March 10, 2025, with a funding range of $2,500 to $15 million available through January 14, 2033. Interested parties can direct inquiries to Alexander Beraud at alexander.beraud@nih.gov or Brian Madgey at brian.madgey@nih.gov.
    Clinical Studies of Infectious Agents, Vaccines and Antivirals in Adult and Pediatric Human Subjects
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID), is seeking small business contractors to conduct clinical studies focused on infectious agents, vaccines, and antivirals for both adult and pediatric populations. The primary objectives include evaluating the safety, immunogenicity, and efficacy of vaccines against various viruses, including emerging threats like Zika, with a project duration anticipated from August 2026 to August 2033 under a cost-reimbursement IDIQ contract structure. This initiative builds on decades of NIH-led research and aims to advance medical research through strategic partnerships with capable small businesses. Interested parties should submit their capability statements, including prior experience and qualifications, to the primary contact, Uju Obii-Obioha, at uju.obii-obioha@nih.gov, by the specified deadlines.
    2026 NIAID DMID Omnibus Broad Agency Announcement
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institute of Allergy and Infectious Diseases (NIAID), is soliciting proposals for the 2026 DMID Omnibus Broad Agency Announcement (BAA) aimed at advancing research and development of medical countermeasures against antimicrobial-resistant pathogens and viruses with pandemic potential. The BAA encompasses two primary research areas: Research Area 001 focuses on developing therapeutics, vaccines, and diagnostics for antimicrobial-resistant bacterial and fungal pathogens, while Research Area 002 targets the creation of Direct Acting Antivirals for viruses of pandemic potential. This initiative is critical for addressing public health challenges related to infectious diseases, with an estimated funding of $28.5 million available for awards in fiscal year 2026. Proposals for Research Area 001 are due by February 21, 2025, and for Research Area 002 by January 21, 2025; interested parties can contact Swee L. Teo at teosl@niaid.nih.gov or Brian Madgey at brian.madgey@nih.gov for further information.
    NUcleic acid Linked Immuno-Sandwich Assay Reagents
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking proposals for the procurement of NUcleic acid Linked Immuno-Sandwich Assay Reagents, aimed at enhancing biomarker discovery for neurodegenerative disease research at the Center for Alzheimer’s Disease and Related Dementias (CARD). The acquisition includes the Alamar NULISAseq Inflammation Panel, with a requirement for 30 units that must demonstrate high sensitivity in analyzing over 250 proteins from minimal sample volumes, ensuring compatibility with the ARGO proteomics platform. This procurement is critical for advancing research capabilities in the detection of biomarkers related to Alzheimer’s Disease and Related Dementias (ADRD). Interested vendors must submit their quotations by January 22, 2025, at 12:00 PM Eastern Time, to Andrea Clay at amcgee@nida.nih.gov, and must comply with all specified federal regulations and provisions outlined in the solicitation.
    Diagnostic laboratory Testing
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), intends to negotiate a sole-source contract with Antech Diagnostics, Inc. for one year of diagnostic laboratory testing services at the NIH Animal Center in Poolesville, Maryland. The required services include clinical pathological evaluations of blood and other bodily fluids from non-human primates, encompassing tests such as Complete Blood Counts, Blood Chemistry Analysis, and Urinalysis, which are critical for ensuring accurate and timely results in research. This procurement is justified under the statutory authority allowing non-competitive procurement due to the necessity for continuity in laboratory services, and interested parties are invited to submit capability statements by January 23, 2023, to Calvin Robinson at calvin.robinson@nih.gov for consideration.
    Q515--Molecular analyzers, reagents and maintenance
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is initiating a sole-source acquisition with Roche Diagnostics Corp. for the provision of Microbiology Molecular Diagnostics, which includes specific molecular analyzers, reagents, and maintenance for various FDA-approved real-time PCR tests. The procurement aims to support critical healthcare services by providing qualitative and quantitative testing for conditions such as HIV, COVID-19, HPV, and hepatitis viruses, highlighting the unique capabilities of Roche Diagnostics Corp. as the sole provider for these essential diagnostic tools. Interested parties may express their interest by contacting Contract Officer James E. Boles Jr. at james.boles2@va.gov by 1:00 p.m. local time on January 27, 2025, although this notice does not constitute a request for competitive bids.
    National Institute of Environmental Health Sciences (NIEHS) Assessment of Immunotoxicity – In Vitro and In Vivo Assessment of Immune Function
    Health And Human Services, Department Of
    The National Institute of Environmental Health Sciences (NIEHS), part of the Department of Health and Human Services, is seeking proposals for a contract focused on the assessment of immunotoxicity through both in vitro and in vivo studies of immune function. The primary objective is to evaluate how selected chemical agents modify immune responses, utilizing established testing models to enhance understanding of immunotoxicity while aiming to reduce animal use in research. This initiative is critical for advancing toxicological assessments and ensuring compliance with federal standards in environmental health research. Interested contractors must submit their proposals by 4:00 PM EST on February 18, 2025, and can direct inquiries to Adam Muhsin at adam.muhsin@nih.gov or Erica Kitzmiller at erica.kitzmiller@nih.gov.
    Long Read Sequencing Kits
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is seeking proposals for the procurement of Long Read Sequencing Kits, specifically Oxford Nanopore brand or equivalent items, to support research on neurodegenerative diseases. The acquisition aims to supply the Center for Alzheimer’s Disease and Related Dementias with kits that will facilitate the identification of causative genes linked to Alzheimer's Disease and related disorders, utilizing long-read sequencing technology. This procurement is critical for advancing research in understanding and treating neurodegenerative diseases, with an anticipated delivery of the first order by September 30, 2025, and options for additional orders in subsequent years. Interested vendors must submit their quotations by 12:00 p.m. EST on January 24, 2025, to Andrea Clay at amcgee@nida.nih.gov, referencing Solicitation Number 75N95025Q00095.
    Serological Assays for the Detection and Characterization of Influenza Viruses
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is soliciting proposals for a contract focused on serological assays for the detection and characterization of influenza viruses. The primary objectives include performing hemagglutination inhibition assays on human serum samples and developing new serology platforms that are comparable to existing methods. This initiative is crucial for enhancing influenza surveillance and vaccine effectiveness studies, addressing ongoing public health challenges. Interested parties must submit a Letter of Interest by 2:00 PM EST on February 7, 2025, and can contact Jennifer Gartzke at jgartzke@cdc.gov or 404-498-0020 for further information.
    Hardy Diagnostic Reagents and Supplies
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to award a sole-source contract to Hardy Diagnostics for the procurement of culture media and organism supplies necessary for cGMP Sterility Testing Services. The primary objective is to ensure compliance with FDA regulations by utilizing cGMP quality materials that have been rigorously validated, as these supplies are critical for the isolation and identification of pathogens affecting critically ill patients. The contract will cover a base period of twelve months with an option for an additional three months, and interested vendors capable of providing similar products are encouraged to submit capability statements by the specified deadline. For further inquiries, potential respondents may contact Kimala Winfield at kimala.winfield@nih.gov or Malinda Dehner at dehnerm@cc.nih.gov.